Weeks Brad Allan purchased $5K of RDGL
Weeks Brad Allan (President) purchased 92,000 shares of VIVOS INC (RDGL) at $0.05 across 2 trades over 2026-07-21 to 2026-07-22.
VIVOS INC
No enriched coverage for $RDGL in the last 7 days.
Weeks Brad Allan (President) purchased 92,000 shares of VIVOS INC (RDGL) at $0.05 across 2 trades over 2026-07-21 to 2026-07-22.
Korenko Michael K (CEO AND PRESIDENT) purchased 200,000 shares of VIVOS INC (RDGL) at $0.06 on 2026-07-15.
Weeks Brad Allan (President) purchased 60,000 shares of VIVOS INC (RDGL) at $0.08 across 2 trades over 2026-07-09 to 2026-07-10.
Recent RDGL coverage spans insider activity and financial news.
In the last 30 days, RDGL insiders filed 4 SEC Form 4 transactions — 4 purchases ($17K) and no sales. The most active reporter was Weeks Brad Allan, President, with 3 filings.
A small open-market insider buy is disclosed, but it is not a 10b5-1 plan and may signal confidence; however, the dollar value is modest.
An insider open-market purchase signals management confidence, but the disclosed dollar amount is small and lacks guidance or operational catalysts.
Insider open-market buying at a fixed low price can be a modest bullish signal, but the disclosed dollar amount is small and not a fundamental catalyst.
Vivos Inc. (RDGL) has reported positive results from its first human trial of RadioGel® therapy, which could be a breakthrough in cancer treatment. This development may lead to increased investor interest and a potential upward movement in stock price.
alphai scores every news story that mentions RDGL with an AI model for sentiment and relevance, and aggregates insider trades from VIVOS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Weeks Brad Allan (President) purchased 92,000 shares of VIVOS INC (RDGL) at $0.05 across 2 trades over 2026-07-21 to 2026-07-22.
1 min readKorenko Michael K (CEO AND PRESIDENT) purchased 200,000 shares of VIVOS INC (RDGL) at $0.06 on 2026-07-15.
1 min readWeeks Brad Allan (President) purchased 60,000 shares of VIVOS INC (RDGL) at $0.08 across 2 trades over 2026-07-09 to 2026-07-10.
2 min readIn what could prove to be a transformational development in cancer treatment, Vivos Inc. RDGL, the maker of the RadioGel® Precision Radionuclide Therapy™, has reported positive results from its first-ever human trial.
3 min read